Hoechst Aktiengesellschaft

Herbert Siegel

Wolfgang Raether

Hermann J Gerhards

Walter Dittmar

Klaus-Dieter Kampe

Patricia Usinger

Burkhard Sachse

Erwin Weiss

Harald Berger

Ulrich Schacht

Margret Leven

Ernold Granzer

Siegfried Scheler

Hans G Alpermann

Hans-Georg Alpermann

Gerhard Buhr

Klaus Bergmann

Helmut Lenz

Pharmaceutical products containing a 7-diphenylmethylenebicycloheptane or 7-diphenylmethylenebicycloheptene derivative of the formula I ##STR1## in which A, B, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the stated meanings, or a physiologically tolerated acid addition salt of these compounds, and the use thereof as hypolipidemics are described. In addition, new 7-diphenylmethylenebicycloheptane and -heptene derivatives of the formula Ia ##STR2## in which A, B, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the stated meanings, and the physiologically tolerated acid addition salts thereof, as well as processes for the preparation thereof, are described.

7-diphenylmethylenebicycloheptane or 7-diphenylmethylenebicylcoheptene

The invention relates to novel radiation-sensitive compounds which are esters or amides of a 1,2-naphthoquinone-(2)-diazide-4-sulfonic acid of the general formula ##STR1## in which R.sub.1 and R.sub.2 are identical or different and denote hydrogen, an alkyl group, an alkyl ether group or an alkyl thioether group whose carbon chains may be interrupted by ether oxygen atoms, an acylamino group, carboxylic acid ester group, sulfonic acid ester group or sulfonamide group,

Radiation-sensitive compounds, radiation-sensitive mixture prepared

Arylmethylazoles of the formula I ##STR1## in which Aryl is (substituted) phenyl or naphthyl;

Arylmethylazoles and their salts, agents which contain these compounds,

The invention relates to a process for preparing 1,2-naphthoquinone-(2)-diazide-4-sulfonic acid esters of the general formula I ##STR1## which are substituted in at least one of the positions 5, 6, 7 or 8 by R=halogen, alkoxy groups or alkoxycarbonyl groups and in which X denotes an aryl group. The process comprises steps in which

Process for preparing substituted

Arylmethylazole preparation processes

1-(1-Aryl-2-hydroxyethyl)-imidazoles and salts thereof, processes for the preparation thereof, medicaments containing these compounds, and the use thereof. The invention relates to 1-(1-aryl-2-hydroxyethyl)-imidazoles of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, Q, W, X and Y have the meanings specified, and also to medicaments based on these compounds, in particular those having an antimycotic and an antidepressive action.

1-(1-aryl-2-hydroxyethyl)-imidazoles and salts thereof, medicaments

Arylmethylazoles and their salts, processes for their preparation,

The invention relates to a process for the preparation of 2-chloroethanephosphonyl dichloride by reaction of an ester of 2-chloroethanephosphonic acid of the formula ##STR1## or a mixture of the two esters with thionyl chloride at a temperature of 60.degree. to 160.degree. C. Phosphine oxides are employed as catalysts therein. The thionyl chloride is added to the initially introduced ester.

Process for the preparation of 2-chloroethanephosphonyl dichloride

Alkenylazoles of formula I a/b ##STR1## in which X/Y is H, alkyl, phenyl, Hal, alkoxy or alkylthio; Z is CH or N; R is alkyl or a bridged (CH.sub.2).sub.m chain; and A is alkylene or a bridged alkylene chain; and the salts of these alkenylazoles are antimycotic agents or fungicides. They are obtained by elimination of water from the compounds II ##STR2##

Alkenylazoles, a process for their preparation and their use

The invention relates to a process for the preparation of vinylphosphonic dichloride through elimination of hydrogen chloride from 2-chloroethanephosphonic dichloride in the presence of catalysts. The catalysts used are tertiary phosphines, quaternary ammonium or phosphonium salts or alkali metal or alkaline-earth metal halides. When triphenyl phosphine is used as the catalyst, the reaction is carried out under reduced pressure at a temperature of 130.degree. to 166.degree. C. and the vinylphosphonic dichloride produced is simultaneously removed by distillation under reduced pressure. When the other catalysts are used, the process can be carried out at atmospheric pressure or reduced pressure and at temperatures of about 130.degree. to 220.degree. C. and the vinylphosphonic dichloride produced can be removed by distillation simultaneously with or subsequent to the reaction.

Process for the preparation of vinylphosphonic dichloride

The invention relates to a process for the preparation of vinylphosphonic dichloride, in which a 2-chloroethanephosphonate of the formula ##STR1## or a mixture of the two esters, is reacted with thionyl chloride at a temperature of 60.degree. to 160.degree. C. in the presence of a catalyst which contains tertiary phosphines, quaternary ammonium or phosphonium salts or alkali metal or alkaline-earth metal halides. During this reaction, any thionyl chloride which may be present is removed by distillation subsequent to this reaction, the mixture remaining is heated to 140.degree. to 200.degree. C., and the vinylphosphonic dichloride produced during this is removed by distillation.

The invention relates to a process for the preparation of 2-chloroethanephosphonic dichloride through reaction of a 2-chloroethanephosphonate of the formula ##STR1## or a mixture of the two esters, with thionyl chloride at a temperature of 60.degree. to 160.degree. C. In this reaction, tertiary phosphines, quaternary ammonium or phosphonium salts or alkali metal or alkaline-earth metal halides are employed as catalysts. The thionyl chloride is introduced into the initially introduced ester.

Process for the preparation of 2-chloroethanephosphonic dichloride

N-Bicycloheptyl- and N-bicycloheptenyl-imidazoles of the formula I ##STR1## in which A, B, R.sup.1, R.sup.2 and n have the indicated meanings, and their physiologically tolerated salts, a process for the preparation of these compounds, pharmaceutical products based on these compounds, and their use as medicaments, in particular for the treatment of disturbances of the serum lipoprotein spectrum, are the subject-matter of the invention.

Growing community of inventors

Hofheim am Taunus, Germany

Herbert Siegel